^
    Back
    Association details:
    Biomarker:LRP1B mutation
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Imbruvica (ibrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Transl Oncol
    Title:

    Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation

    Published date:
    12/06/2020
    Excerpt:
    ...141 patients were enrolled and treated with daily oral ibrutinib (420 mg or 560 mg) plus intravenous nivolumab...In DLBCL, WES analyses demonstrated that mutations in...KLHL14 (30.0% vs. 0%; p = 0.046), and LRP1B (30.0% vs. 6.2%; p = 0.264) were more frequent in responders...
    DOI:
    10.1016/j.tranon.2020.100977